Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Weaver

Showing results (141-150 of 173) with videos related to

Pageof 18
Sort By:
Journal of Medicinal Chemistry|November 26, 2014
Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM)Lindsey C Morris, Kellie D Nance, Patrick R Gentry, et al.
ACS Chemical Neuroscience|June 5, 2013
ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in miceKristian Kaufmann, Ian Romaine, Emily Days, et al.
Circulation Research|April 14, 2023
Enhanced Mitochondria-SR Tethering Triggers Adaptive Cardiac Muscle RemodelingZuzana Nichtová, Celia Fernandez-Sanz, Sergio De La Fuente, et al.
Molecular Pharmacology|June 14, 2018
Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992Sujay V Kharade, Haruto Kurata, Aaron M Bender, et al.
Nature Communications|March 12, 2025
VDAC2 and Bak scarcity in liver mitochondria enables targeting hepatocarcinoma while sparing hepatocytesShamim Naghdi, Piyush Mishra, Soumya Sinha Roy, et al.
ACS Chemical Neuroscience|October 1, 2011
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous systemEvan P Lebois, Thomas M Bridges, L Michelle Lewis, et al.
Molecular Pharmacology|June 10, 2026
Identification of potent and selective small molecule TALK-1 inhibitors that promote β-cell functionArya Y Nakhe, Jordyn R Dobson, Prasanna K Dadi, et al.
The Journal of Biological Chemistry|July 29, 2011
Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channelsMelissa Miller, Jie Shi, Yingmin Zhu, et al.
Journal of Medicinal Chemistry|August 22, 2003
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibitionYong-Jin Wu, Carl D Davis, Steven Dworetzky, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neuronsYong-Jin Wu, Christopher G Boissard, Jie Chen, et al.
Pageof 18

Showing results (141-150 of 173) with videos related to

Sort By:
Pageof 18
Journal of Medicinal Chemistry|November 26, 2014
Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM)Lindsey C Morris, Kellie D Nance, Patrick R Gentry, et al.
ACS Chemical Neuroscience|June 5, 2013
ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in miceKristian Kaufmann, Ian Romaine, Emily Days, et al.
Circulation Research|April 14, 2023
Enhanced Mitochondria-SR Tethering Triggers Adaptive Cardiac Muscle RemodelingZuzana Nichtová, Celia Fernandez-Sanz, Sergio De La Fuente, et al.
Molecular Pharmacology|June 14, 2018
Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992Sujay V Kharade, Haruto Kurata, Aaron M Bender, et al.
Nature Communications|March 12, 2025
VDAC2 and Bak scarcity in liver mitochondria enables targeting hepatocarcinoma while sparing hepatocytesShamim Naghdi, Piyush Mishra, Soumya Sinha Roy, et al.
ACS Chemical Neuroscience|October 1, 2011
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous systemEvan P Lebois, Thomas M Bridges, L Michelle Lewis, et al.
Molecular Pharmacology|June 10, 2026
Identification of potent and selective small molecule TALK-1 inhibitors that promote β-cell functionArya Y Nakhe, Jordyn R Dobson, Prasanna K Dadi, et al.
The Journal of Biological Chemistry|July 29, 2011
Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channelsMelissa Miller, Jie Shi, Yingmin Zhu, et al.
Journal of Medicinal Chemistry|August 22, 2003
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibitionYong-Jin Wu, Carl D Davis, Steven Dworetzky, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neuronsYong-Jin Wu, Christopher G Boissard, Jie Chen, et al.
Pageof 18